Tags

Type your tag names separated by a space and hit enter

Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Fertil Steril. 2004 Nov; 82(5):1323-9.FS

Abstract

OBJECTIVE

To test the hypothesis that the concentration of early follicular phase serum antimullerian hormone (AMH) or mullerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome.

DESIGN

Retrospective analysis of day 3 serum samples drawn before treatment.

SETTING

Private ART program.

PATIENT(S)

One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF.

INTERVENTION(S)

Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment.

MAIN OUTCOME MEASURE(S)

Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome.

RESULT(S)

Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes.

CONCLUSION(S)

These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.

Authors+Show Affiliations

ART Unit Eylau la Muette, Clinic La Muette, Paris, France. ahazout@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15533354

Citation

Hazout, André, et al. "Serum Antimüllerian Hormone/müllerian-inhibiting Substance Appears to Be a More Discriminatory Marker of Assisted Reproductive Technology Outcome Than Follicle-stimulating Hormone, Inhibin B, or Estradiol." Fertility and Sterility, vol. 82, no. 5, 2004, pp. 1323-9.
Hazout A, Bouchard P, Seifer DB, et al. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82(5):1323-9.
Hazout, A., Bouchard, P., Seifer, D. B., Aussage, P., Junca, A. M., & Cohen-Bacrie, P. (2004). Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility, 82(5), 1323-9.
Hazout A, et al. Serum Antimüllerian Hormone/müllerian-inhibiting Substance Appears to Be a More Discriminatory Marker of Assisted Reproductive Technology Outcome Than Follicle-stimulating Hormone, Inhibin B, or Estradiol. Fertil Steril. 2004;82(5):1323-9. PubMed PMID: 15533354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. AU - Hazout,André, AU - Bouchard,Philippe, AU - Seifer,David B, AU - Aussage,P, AU - Junca,Anne Marie, AU - Cohen-Bacrie,Paul, PY - 2003/12/30/received PY - 2004/03/22/revised PY - 2004/03/22/accepted PY - 2004/11/10/pubmed PY - 2004/12/29/medline PY - 2004/11/10/entrez SP - 1323 EP - 9 JF - Fertility and sterility JO - Fertil Steril VL - 82 IS - 5 N2 - OBJECTIVE: To test the hypothesis that the concentration of early follicular phase serum antimullerian hormone (AMH) or mullerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome. DESIGN: Retrospective analysis of day 3 serum samples drawn before treatment. SETTING: Private ART program. PATIENT(S): One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF. INTERVENTION(S): Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment. MAIN OUTCOME MEASURE(S): Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome. RESULT(S): Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes. CONCLUSION(S): These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/15533354/Serum_antimüllerian_hormone/müllerian_inhibiting_substance_appears_to_be_a_more_discriminatory_marker_of_assisted_reproductive_technology_outcome_than_follicle_stimulating_hormone_inhibin_B_or_estradiol_ DB - PRIME DP - Unbound Medicine ER -